About the Company
ibio is a contract development and manufacturing organization equipped to take clients from the early stages of product selection through regulatory approval and commercial product launch. ibio’s technology platform and facility capabilities are applicable to the development of biotherapeutics, vaccines, diagnostic products, and certain types of medical devices – and often provide significant time and value advantages over traditional approaches. ibio’s lab to launch capabilities assure the most rapid manufacturing support to reach the clinic. ibio’s team is comprised of knowledgeable protein scientists, microbiologists and manufacturing and regulatory experts, all of whom add significant expertise and value throughout the entire process. the same team and facility that produces preclinical and clinical material will be the same team producing your product for market launch; contributing to the seamless scale-up process the ibio technology platform creates.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $IBIO News
iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka
BRYAN, Texas and SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody ...
iBio, Inc. (IBIO) Stock Historical Prices & Data - Yahoo Finance
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
iBio Inc
Picking the best bond ETF can be hard with so many options available. Here's what the experts suggest focusing on.
Why Is iBio (IBIO) Stock Down 41% Today?
Ibio (NYSEMKT:IBIO) stock is falling hard on Tuesday after the biotechnology company announced the pricing of a public share offering. That offering has the company selling 2.25 million shares of ...
C4 Therapeutics Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Snap Inc Class A
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
iBio, Inc.: iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka
About iBio, Inc. iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of ...
iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka
BRYAN, Texas and SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision ...
Loading the latest forecasts...